Abstract: Polyelectrolyte nanoparticles are generated to stabilize foam for use in enhanced oil recovery. Stability is further enhanced by optimizing pH and a ratio of polycationic and polyanioinic materials, resulting in stronger and longer lasting foams in the presence of crude oil. Use of these nanoparticles results in negligible damage to formation permeability.

Abstract: A device for measuring the pressure applied between a user's tongue and palate includes a body shaped to fit complimentarily against the user's palate and a pressure sensor affixed to the body such that the device has a total thickness less than 4 millimeters.

Abstract: The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.

Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.

Abstract: Implementations of the present invention relate to apparatuses, systems, and methods for constructing and using a metastatic mimetic device. The device includes at least one chamber with a gate structure that allows a channel to selectively allow fluid communication between an interior of the chamber and an exterior of the chamber. The channel includes a porous member extending across a cross-section of the channel to control flow rates or allow the mimetic device to replicate transport across a member.

Abstract: The disclosure is directed to methods and compositions delaying the gelation of polymers in water flooding by sequentially or co-injecting a carboxylate-containing polymer solution, a gel-delaying polymer, and gelation agent into a hydrocarbon reservoir. Delays of weeks are observed.

Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, oral mucositis, mucositis, and proctitis by the administration of a compound Yel002/BCN057 or an analog thereof.

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

Abstract: In a first aspect, the present invention is directed to a process for forming a metal alloy catalyst. Another aspect of the present invention is directed to a process for oxidizing a substrate that includes contacting a substrate with an oxidant in the presence of a metal alloy catalyst to form one or more carboxylic acids. Suitable substrates include sugars, polyols, furfural alcohols, and polyhydroxycarboxylic acids. The oxidation process may use the alloy catalyst formed from the process of the first aspect of the invention.

Abstract: Provided are platinum(IV) compounds of Formula I or pharmaceutically acceptable salts thereof. Also provided are compositions including such compounds as well as methods of using the same.

Abstract: The invention provides an isolated chimeric virus comprising bocavirus capsid protein and a recombinant adeno-associated viral (AAV) genome, an isolated rBoV comprising human bocavirus capsid protein and a recombinant BoV genome, and uses therefor. For example, the chimeric virus may be employed to deliver transgenes, such as those encoding therapeutic or prophylactic gene products, to mammalian cells.

Abstract: N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provides as is their use in the treatment of diseases such as diabetes, Alzheimer's, Parkinson's, hemophilia, lysosomal storage diseases and cancer.

Abstract: A capture device for capturing a biological substance can include: a substrate; a graphene-oxide layer on the substrate; at least one polydopamine polymer coupled with the graphene-oxide; and at least one targeting receptor coupled to the polydopamine(s), wherein the targeting receptor is capable of targeting/binding with a target biological substance. The graphene-oxide may be covalently coupled with the substrate and polydopamine, and the polydopamine may be covalently coupled with the targeting receptor. The targeting receptor can be an antibody or fragment thereof. The target biological substance can be an exosome. The substrate can be a particle (e.g., magnetic, such as magnetically responsive) or a surface in a microfluidic channel. The surface can be a top surface of a post, the post having a Y-shaped cross-sectional profile. In one aspect, the substrate is a particle. The capture device can include the target biological substance bound to the targeting receptor.

Abstract: The disclosure relates to nerve derived adult pluripotent stem cells characterized by expression of Oct4, Sox2, c-Myc, and Klf4, methods for obtaining them, and their use.

Abstract: A peptide can have a sequence of one of SEQ ID NOs: 78-91. A conformationally-constrained kinked peptide includes: a conformationally-constraining portion and a kinked portion linked to the conformationally-constraining portion that conformationally constrains the kinked portion having a peptide sequence of one of SEQ NOs: 78-97. A cell-targeting compound can include a conformationally-constrained kinked peptide having a peptide sequence of one of SEQ ID NOs: 78-97. The peptide sequence can be one of SEQ ID NOs: 78-97, or 78-91, or 92-97. A cell-targeting compound can include a conformationally-constrained kinked peptide linked to a branched linker with one branch arm linked to a specific targeting moiety and one branch arm linked to a general targeting moiety. The specific targeting moiety can be an antibody. The general targeting moiety can be a lipid or cholesterol derivative.

Abstract: The instant application relates to nanogels or compositions that hold multivalent metal ions until some level of nanogel degradation has occurred, then slowly release the multivalent metal ions for gelation with carboxylate containing polymers. Compositions comprising such nanogels, together with polymers that can be crosslinked with multivalent metal ions, allow the deployment of such mixtures in various applications, and greatly increased gelation times.

Abstract: An implantable composition can include methacrylated solubilized devitalized cartilage (MeSDVC) with or without devitalized cartilage (DVC) particles. These compositions can be hydrogel precursors. After implantation, the MeSDVC may be crosslinked so as to form a hydrogel. The crosslinked hydrogel can include the DVC particles. A hydrogel precursor matrix (e.g., not crosslinked) can include a crosslinkable substance that can be crosslinked into a hydrogel, where DVC particles are included in the precursor matrix. The hydrogel precursor matrix can be located in a tissue defect site, such as a hole or recess in a cartilage or bone, and then crosslinked into a hydrogel that has the DVC particles therein.

Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.

Abstract: A method for processing lignin may comprise flowing a lignin composition comprising a lignin polymer and a solvent through a reaction chamber of a continuous flow reactor, the lignin polymer comprising hydroxycinnamic groups bound to a polymeric backbone; flowing ozone through the reaction chamber containing the lignin composition under conditions to maximize oxidative cleavage of the hydroxycinnamic groups to produce one or more types of aromatic monomers while minimizing oxidative cleavage of the polymeric backbone; and collecting the one or more types of aromatic monomers, e.g., by a size-selective membrane separation device.